WCLC: Merck analyses throw doubt on new biomarker's utility

Looking to find their niche in the ultra-lucrative non-small cell lung cancer market, some immuno-oncology companies have turned to investigational biomarker TMB, or tumor mutational burden, in hopes of ID’ing patient populations for whom their treatments might be more effective. But lung cancer behemoth Merck is throwing cold water on that idea.